AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02864290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1235
Description: intravenous (IV) infusion
Study NCT05063058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molecular guided therapy
Description: Biomarker-driven therapy according to recommandations of the precision oncology tumor board including MEK Inhibitors (Trametinib 2 mg/d, Selumetinib 75 mg 2/d), MET Inhibitors (Crizotinib 250 mg 2/d, or Cabozantinib 60mg/d), RAS Inhibitor (Sorafenib 400 mg 2/d), Cell cycle Inhibitor (Palbociclib 125 mg/d) and Checkpoint Inhibitor (Nivolumab 240 mg every 2 weeks).
Study NCT02374528 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy
Description: Negative pressure wound therapy (NPWT) is the application of suction (negative pressure) to wounds with skin grafting.
Study NCT02374528 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard pressure bolster dressing
Description: This method is traditional used in skin grafting wound.
Study NCT04033497 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Magnetic Resonance Imaging will generate imaging of the brain to identify recurrence of tumor.
Study NCT06654570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravaginal estrogen during adjuvant letrozole
Description: Postmenopausal patients undergoing adjuvant letrozole therapy and experiencing VVA symptoms were treated with vaginal estradiol for 12 weeks. Gynecologic examination and symptom screening were conducted at baseline and after 12 weeks. Serum E2 levels were analyzed at baseline, and at two, four, eight, and 12 weeks. E2 levels were measured using both a routine liquid chromatography-tandem mass spectrometry (LC-MS/MS) method and a highly sensitive (hsE2-MS) LC-MS/MS method.
Study NCT01104311 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aggressive BP lowering
Description: adjust the amount and number of antihypertensive drugs to lowering of systolic blood pressure to target level
Study NCT01104311 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modest blood pressure lowering
Description: adjust the amount and number of antihypertensive drugs
Study NCT03524729 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rocker bottom shoe
Description: Walking shoe with a anterior posterior rocker sole.
Study NCT03524729 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ankle foot orthosis
Description: Dynamic carbon fiber ankle brace.
Study NCT03524729 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard walking shoe
Description: Standard walking shoe (control shoe) with no rocker sole.
Study NCT03524729 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Standard walking shoe
Description: Standard walking shoe (control shoe) with no rocker sole.
Study NCT03632473 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: multimodal evoked potentials (mmEP)
Description: combination of visual evoked potentials (VEP) and motor evoked potentials (MEP) or the combination of VEP, MEP and somato-sensory evoked potentials (SSEP)
Study NCT03458208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Third Intervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fed condition
Study NCT03458208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage®
Description: Fourth Intervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fed condition
Study NCT01026831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preservative-Free Tafluprost
Description: One drop of preservative-free vehicle per eye in the morning, and one drop of preservative-free tafluprost (0.0015%) per eye in the evening for 12 weeks
Study NCT01026831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: timolol
Description: One drop of preservative-free timolol maleate (0.5%) per eye twice daily for 12 weeks
Study NCT01708109 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no measures taken to clear bile ductus
Description: biliary calculus remain
Study NCT01708109 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: clearance of bile ductus
Description: biliary calculus removed at surgery
Study NCT04249687 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin
Description: neuromodulator
Study NCT04249687 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT02611388 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEAS (transcutaneous electrical acupoint stimulation)
Description: 2/10HZ Electric stimulation was given through electrode attached to specific acupoints
Study NCT02611388 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEAS (transcutaneous electrical acupoint stimulation)
Description: 10/50HZ Electric stimulation was given through electrode attached to specific acupoints
Study NCT02611388 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: fake stimulation
Description: Patients were only attached electrodes without electric current
Study NCT00250835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemotherapy, Celecoxib, and Radiation
Description: Enrolled rectal cancer patients are treated with concurrent chemoradiation and celecoxib pre-operatively for at least 14 days. Definitive surgery is performed within 6 weeks from the end of treatment.
Study NCT03514628 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: The Valsalva strain will be produced using Standard Care techniques
Study NCT03514628 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valsalva Assist Device (VAD)
Description: Use of Valsalva Assist Device (VAD) to generate VM
Study NCT03550482 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ONCOXIN®
Description: Adjuvant chemotherapy regimen (XELOX or paclitaxel+carboplatin) + Oncoxin 25 ml twice daily for 20 days. In case of nausea/vomiting after ONCX use patients were advised to dilute it in water, juice or milk. Patients with BMI \<20 and serum albumin levels \<30 g/l received nutritional support.
Study NCT04357821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Intervention
Description: 1. IL-12 adjuvanted p24CE DNA prime (p24CE/IL-12) at Weeks 0 and 4~2. IL-12 adjuvanted DNA boost (p24CE plus p55gag) at Week 12~3. MVA/HIV62B (MVA62B) boost at Week 20~4. single dose of two bNAbs (VRC07-523LS and 10-1074, which target CD4 binding site and V3 loop, respectively) at week 24 with a TLR9 agonist (lefitolimod) administered weekly between Weeks 24 and 33 (10 doses)~5. ATI with single dose of VRC07 and 10-1074 at Week 34
Study NCT01335763 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Insulin glargine
Description: 10 units at bedtime of insulin glargine will be prescribed to the patients who has HbA1c levels of 7.5-11%. Insulin glargine dose is going to be titrated by increments of 1 unit daily by the patient to achieve a morning fasting glucose of \<=5.5mmol/L
Study NCT02152852 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker Intervention
Description: For the intervention group, a trained Community Health Worker (CHW) will provide education, support and service coordination through in-home visits. The CHW will first make an in-home assessment visit. At the assessment visit, the participant has the opportunity to ask questions and sign written consent. During this visit, the CHW assesses the participant's history with diabetes, medication adherence, self-management activities, healthcare utilization and will administer a finger stick blood test for HbA1c and a full lipid panel. After enrollment, the participant receives up to five follow-up educational visits 0.5, 1.5, 3.5, 7 and 10 months later. In addition to scheduled visits, the CHWs work with their participants on an as-needed basis via telephone, or additional home visits.
Study NCT03270735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Snake venom thrombin (Treatment)
Description: Snake venom thrombin
Study NCT03270735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No snake venom thrombin
Study NCT04036968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Within-subject test of blinded study medications
Description: Within-subject double-blind, double-dummy, study design wherein all participants received all doses in 8-hour outpatient sessions. Primary outcomes assessed during 8-hour outpatient sessions and included laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition.
Study NCT04036968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Within-subject test of blinded study medications
Description: Within-subject double-blind, double-dummy, study design wherein all participants received all doses in 8-hour outpatient sessions. Primary outcomes assessed during 8-hour outpatient sessions and included laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition.
Study NCT04036968 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Within-subject test of blinded study medications
Description: Within-subject double-blind, double-dummy, study design wherein all participants received all doses in 8-hour outpatient sessions. Primary outcomes assessed during 8-hour outpatient sessions and included laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition.
Study NCT04414800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Distilled water
Study NCT04414800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 1 mg/kg intranasal ketamine
Study NCT04414800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 1μg/kg intranasal fentanyl
Study NCT01553981 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: Tab. Tadalafil 20 mg every other day for 6 months
Study NCT01553981 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Shape , size, color and odor matched Tab. of inert material every other day for 6 months
Study NCT01201161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intravitreal injection of ranibizumab 0.05 ml (0.5 mg) one week before pars plana vitrectomy
Study NCT01201161 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham injection
Description: Simulation of intravitreal injection one week before pars plana vitrectomy
Study NCT01208714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal medical therapy
Description: Optimal medical therapy, including optimal antihypertensive therapy as defined by ESH/ESC Guidelines Mancia G. J Hypertens 2007; 25: 1105), antiplatelet and, if necessary, hypolipemic and hypoglycemic treatment.~All patients will receive antiplatelet treatment with the same dose of aspirin (100 mg o.d.) or ticlopidine (250 mg b.i.d) if intolerant ASA, or clopidogrel (75 mg o.d.), if intolerant to ASA and ticlopidine, throughout the study period. LDL-cholesterol will be lowered to below 100 mg/dl, homocysteine if elevated will be lowered and treatment for diabetes will be optimized (HbA1c \< 6.5%).
Study NCT01208714 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: revascularization
Description: The patients randomized to this treatment will undergo digital scan angiography (DSA) and PTA with stenting of the renal artery. PTA will be performed at the ostium or at truncular level. Stenoses involving more distal arterial vessels will be recorded and considered for data analysis but will not be treated. The patients randomized to revascularization will continue on their antihypertensive drug regimen. The dose and number of drugs will be down-titrated with the aim of pursuing the target BP values.
Study NCT00750633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidex otic solution
Description: 4 drops in the infected ear(s) twice daily (morning and evening) for 7 days
Study NCT00750633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin otic solution
Description: 4 drops in the infected ear(s) twice daily (morning and evening) for 7 days
Study NCT00750633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone phosphate otic solution
Description: 4 drops in the infected ear(s) twice daily (morning and evening) for 7 days
Study NCT00750633 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tympanostomy tubes
Description: Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media with effusion in children
Study NCT00750633 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tympanostomy tubes
Description: Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media with effusion in children
Study NCT03320759 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational therapy rehabilitation
Description: Participants in the experimental arm will receive occupational therapy that is individualized to each participant's needs from week 4 post-decompression surgery until week 12.
Study NCT01681433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OGX-427
Description: OGX-427 started within 7 days of randomization, three loading doses of 600 mg IV within Week 1 if possible (up to 10 days of initiating treatment), followed by weekly doses of 800 mg IV
Study NCT01681433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone Acetate
Description: Standard therapy: Abiraterone Acetate 1000 mg PO daily
Study NCT01681433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Standard therapy: Abiraterone Acetate 1000 mg PO daily
Study NCT01681433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Standard therapy: Prednisone 10-20 mg PO daily
Study NCT01681433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Standard therapy: Prednisone 10-20 mg PO daily
Study NCT02820428 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Healthy participants
Description: Semi-structured interview
Study NCT02423915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 by vein on Day -12 for for participants with CD20+ malignancies.
Study NCT02423915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/m2 by vein on Days -8 to -5.
Study NCT02423915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/kg by vein on Day -8.
Study NCT02423915 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Radiation
Description: 2 Gy delivered on Day -4.
Study NCT02423915 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fucosylated Regulatory T Cells
Description: Phase I: Participants treated at cell dose level 1: 1 x 10\^6/kg Fucosylated T-reg cells on Day -1.~Phase II: Participants treated at cell dose level 2: 1 x 10\^7/kg Fucosylated T-reg cells on Day -1.
Study NCT02423915 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cord Blood Infusions
Description: Cord blood transplant, MRD, or MUD infused on Day 0.
Study NCT02423915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: 15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or mouth from Day -3 to Day +100 in the absence of GVHD.
Study NCT02423915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: 12 mg by mouth load followed by 4 mg by mouth daily from Day -3 to Day +180 in the absence of GVHD.
Study NCT02423915 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Bone marrow aspiration performed at 1, 3, 6, and 12 months after transplant to check status of disease.
Study NCT02423915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 5 mcg/kg/day subcutaneously beginning on D+0, and continuing until absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days.
Study NCT02423915 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-Fucosylated Regulatory T Cells
Description: Phase I: Participants treated at cell dose level 1: 1 x 10\^7/kg Non-Fucosylated T-reg cells on Day -1.~Phase II: Participants treated at cell dose level 2: 1 x 10\^7/kg Non-Fucosylated T-reg cells on Day -1.
Study NCT02931058 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Two knee-extension exercise sessions per week.
Description: Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band.
Study NCT02931058 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Four knee-extension exercise sessions per week.
Description: Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band.
Study NCT02931058 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Six knee-extension exercise sessions per week.
Description: Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band.
Study NCT02803944 — intervention group
Intervention type: DRUG
Intervention: Azithromycin
Study NCT03070847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Dose: 5mg/kg
Study NCT03070847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Dose: 10mg/kg
Study NCT03070847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride
Description: Tranexamic Acid would be diluted in 0,9% Sodium Chloride (0,9% NaCl) to cumulative volume of 20 ml.
Study NCT03070847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Chloride
Description: Tranexamic Acid would be diluted in 0,9% Sodium Chloride (0,9% NaCl) to cumulative volume of 20 ml.
Study NCT01358864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: BI 201335 once a day (QD) for 24 weeks
Study NCT01358864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon-alpha (IFN)
Description: Pegylated Interferon-alpha for 48 weeks
Study NCT01358864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Interferon-alpha (IFN)
Description: Pegylated Interferon-alpha for 48 weeks
Study NCT01358864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin (RBV) for 24 or 48 weeks
Study NCT01358864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin (RBV)
Description: Ribavirin (RBV) for 24 or 48 weeks
Study NCT01358864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo to BI201335 for 24 weeks
Study NCT01964014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: advagrf
Description: All enrolled subjects will discontinue the existing Tacrolimus preparations for 6 months from enrollment and be converted to Extended Release Tacrolimus at a biologically equivalent dose. They will also discontinue enteric-coated mycophenolate sdium or mycophenolate sodium and be treated with Sirolimus and observed.~advagrf+sirolimus one time to eat.
Study NCT05428891 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Abrams' needle pleural biopsy (IG-ANPB) versus medical thoracoscopy in the diagnosis of pleural diseases.
Description: We compare the diagnostic efficacy and safety of imaging-guided Abrams needle biopsy with medical thoracoscopy.
Study NCT02285621 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimized brace versus conventional Boston brace
Description: Surface topography using Inspeck cameras allows production of a 3D reconstruction of the patient's trunk, this reconstruction will help to produce the optimized brace. Radiographic and patient-reported data will be gathered and analyzed to observe changes between time points. All radiographs will be taken with an EOS imaging system to allow 3D reconstructions. The SRS-22r will be collected at all clinical visits. Study questions will be aligned as much as possible with other prospective scoliosis protocols so as to minimize patient and surgeon response burden. The study protocol requires no additional visits or radiographs beyond standard of care. Ibuttons are installed in each brace and used to measure the compliance of the patient.